Metastatic chromophobe renal cell carcinoma: Outcome with targeted agents

被引：0
|
作者：
Colomba, E. [1 ]
Albiges, L. [1 ]
Saldana, C. [2 ]
Verhoest, G. [3 ]
Vauleon, E. [4 ]
Bigot, P. [5 ]
Lheureux, S. [6 ]
Berger, J. [7 ]
Barthelemy, P. [8 ]
Escudier, B. [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] CHU Rennes, Rennes, France
[4] Ctr Eugene Marquis, Rennes, France
[5] CHU Angers, Angers, France
[6] Ctr Francois Baclesse, F-14021 Caen, France
[7] CHU Dupuytren, Limoges, France
[8] CHRU Strasbourg, Strasbourg, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2760
引用
收藏
页码：S662 / S662
页数：1
相关论文
共 50 条
  • [41] Simultaneous Chromophobe renal cell carcinoma and squamous renal cell carcinoma
    Funez, Rafael
    Pereda, Teresa
    Rodrigo, Isabel
    Robles, Luis
    Gonzalez, Carlos
    DIAGNOSTIC PATHOLOGY, 2007, 2 (1)
  • [42] Re: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
    Pelzer, Alexandre E.
    EUROPEAN UROLOGY, 2008, 54 (05) : 1200 - 1201
  • [43] Sarcomatoid Chromophobe Renal Cell Carcinoma
    Val-Bernal, Jose-Fernando
    Gomez-Roman, Jose-Javier
    Mayorga-Fernandez, Marta-Maria
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2022, 6 (01): : 92 - 93
  • [44] Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.
    Dudani, Shaan
    de Velasco, Guillermo
    Wells, Connor
    Gan, Chun Loo
    Donskov, Frede
    Porta, Camillo
    Fraccon, Anna
    Pasini, Felice
    Lee, Jae-Lyun
    Hansen, Aaron Richard
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Pal, Sumanta K.
    Yuasa, Takeshi
    Kroeger, Nils
    Kanesvaran, Ravindran
    Reaume, M. Neil
    Canil, Christina M.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement
    Porta, C.
    Tortora, G.
    Linassier, C.
    Papazisis, K.
    Awada, A.
    Berthold, D.
    Maroto, J. P.
    Powles, T.
    De Santis, M.
    MEDICAL ONCOLOGY, 2012, 29 (03) : 1896 - 1907
  • [46] Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement
    C. Porta
    G. Tortora
    C. Linassier
    K. Papazisis
    A. Awada
    D. Berthold
    J. P. Maroto
    T. Powles
    M. De Santis
    Medical Oncology, 2012, 29 : 1896 - 1907
  • [47] TOLERABILITY OF TARGETED AGENTS IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Su, Y.
    Shi, N.
    Landsman-Blumberg, P.
    Poehlein, C.
    Waxman, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 267 - 268
  • [48] Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?
    Pichler, Renate
    Schmidinger, Manuela
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [49] TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents
    Grassi, Paolo
    Verzoni, Elena
    Bearz, Alessandra
    Bracarda, Sergio
    Bregni, Marco
    Buti, Sebastiano
    Cinieri, Saverio
    De Giorgi, Ugo
    Fornarini, Giuseppe
    Galli, Luca
    Milella, Michele
    Morelli, Franco
    Nole, Franco
    Passalacqua, Rodolfo
    Sabbatini, Roberto
    Santini, Daniele
    Salvioni, Roberto
    Cappelletti, Vera
    Ratta, Raffaele
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Safety and efficacy of targeted agents in elderly patients (≥75 years) with metastatic renal cell carcinoma
    Vogl, U. M.
    Bojic, M.
    Lamm, W.
    Harmankaya, K.
    Kramer, G.
    Zielinski, C. C.
    Haitel, A.
    Schmidinger, M.
    ONKOLOGIE, 2010, 33 : 57 - 58
12345